Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS.
Many diseases of the heart are characterised by changes in substrate utilisation, which is regulated in part by the activity of the enzyme pyruvate dehydrogenase (PDH). Consequently, there is much interest in the in vivo evaluation of PDH activity in a range of physiological and pathological states...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Journal article |
| Language: | English |
| Published: |
2011
|
| _version_ | 1797062724132274176 |
|---|---|
| author | Atherton, H Schroeder, M Dodd, M Heather, L Carter, E Cochlin, L Nagel, S Sibson, N Radda, G Clarke, K Tyler, D |
| author_facet | Atherton, H Schroeder, M Dodd, M Heather, L Carter, E Cochlin, L Nagel, S Sibson, N Radda, G Clarke, K Tyler, D |
| author_sort | Atherton, H |
| collection | OXFORD |
| description | Many diseases of the heart are characterised by changes in substrate utilisation, which is regulated in part by the activity of the enzyme pyruvate dehydrogenase (PDH). Consequently, there is much interest in the in vivo evaluation of PDH activity in a range of physiological and pathological states to obtain information on the metabolic mechanisms of cardiac diseases. Hyperpolarised [1-(13)C]pyruvate, detected using MRS, is a novel technique for the noninvasive evaluation of PDH flux. PDH flux has been assumed to directly reflect in vivo PDH activity, although to date this assumption remains unproven. Control animals and animals undergoing interventions known to modulate PDH activity, namely high fat feeding and dichloroacetate infusion, were used to investigate the relationship between in vivo hyperpolarised MRS measurements of PDH flux and ex vivo measurements of PDH enzyme activity (PDH(a)). Further, the plasma concentrations of pyruvate and other important metabolites were evaluated following pyruvate infusion to assess the metabolic consequences of pyruvate infusion during hyperpolarised MRS experiments. Hyperpolarised MRS measurements of PDH flux correlated significantly with ex vivo measurements of PDH(a), confirming that PDH activity influences directly the in vivo flux of hyperpolarised pyruvate through cardiac PDH. The maximum plasma concentration of pyruvate reached during hyperpolarised MRS experiments was approximately 250 µM, equivalent to physiological pyruvate concentrations reached during exercise or with dietary interventions. The concentrations of other metabolites, including lactate, glucose and β-hydroxybutyrate, did not vary during the 60 s following pyruvate infusion. Hence, during the 60-s data acquisition period, metabolism was minimally affected by pyruvate infusion. |
| first_indexed | 2024-03-06T20:49:39Z |
| format | Journal article |
| id | oxford-uuid:3723340b-fce9-4bb4-b2a1-80acf29f7c65 |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-06T20:49:39Z |
| publishDate | 2011 |
| record_format | dspace |
| spelling | oxford-uuid:3723340b-fce9-4bb4-b2a1-80acf29f7c652022-03-26T13:42:10ZValidation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:3723340b-fce9-4bb4-b2a1-80acf29f7c65EnglishSymplectic Elements at Oxford2011Atherton, HSchroeder, MDodd, MHeather, LCarter, ECochlin, LNagel, SSibson, NRadda, GClarke, KTyler, DMany diseases of the heart are characterised by changes in substrate utilisation, which is regulated in part by the activity of the enzyme pyruvate dehydrogenase (PDH). Consequently, there is much interest in the in vivo evaluation of PDH activity in a range of physiological and pathological states to obtain information on the metabolic mechanisms of cardiac diseases. Hyperpolarised [1-(13)C]pyruvate, detected using MRS, is a novel technique for the noninvasive evaluation of PDH flux. PDH flux has been assumed to directly reflect in vivo PDH activity, although to date this assumption remains unproven. Control animals and animals undergoing interventions known to modulate PDH activity, namely high fat feeding and dichloroacetate infusion, were used to investigate the relationship between in vivo hyperpolarised MRS measurements of PDH flux and ex vivo measurements of PDH enzyme activity (PDH(a)). Further, the plasma concentrations of pyruvate and other important metabolites were evaluated following pyruvate infusion to assess the metabolic consequences of pyruvate infusion during hyperpolarised MRS experiments. Hyperpolarised MRS measurements of PDH flux correlated significantly with ex vivo measurements of PDH(a), confirming that PDH activity influences directly the in vivo flux of hyperpolarised pyruvate through cardiac PDH. The maximum plasma concentration of pyruvate reached during hyperpolarised MRS experiments was approximately 250 µM, equivalent to physiological pyruvate concentrations reached during exercise or with dietary interventions. The concentrations of other metabolites, including lactate, glucose and β-hydroxybutyrate, did not vary during the 60 s following pyruvate infusion. Hence, during the 60-s data acquisition period, metabolism was minimally affected by pyruvate infusion. |
| spellingShingle | Atherton, H Schroeder, M Dodd, M Heather, L Carter, E Cochlin, L Nagel, S Sibson, N Radda, G Clarke, K Tyler, D Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS. |
| title | Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS. |
| title_full | Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS. |
| title_fullStr | Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS. |
| title_full_unstemmed | Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS. |
| title_short | Validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13C MRS. |
| title_sort | validation of the in vivo assessment of pyruvate dehydrogenase activity using hyperpolarised 13c mrs |
| work_keys_str_mv | AT athertonh validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT schroederm validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT doddm validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT heatherl validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT cartere validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT cochlinl validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT nagels validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT sibsonn validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT raddag validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT clarkek validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs AT tylerd validationoftheinvivoassessmentofpyruvatedehydrogenaseactivityusinghyperpolarised13cmrs |